Kamada Announces Enrollment of First Patient in its Phase 1/2 Clinical Trial of its Plasma-Derived Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19) in Israel
August 10, 2020 07:00 ET
|
Kamada Ltd.
Study Participants are Hospitalized, Non-ventilated COVID-19 Patients with Pneumonia Encouraging Neutralization Activity Observed with Virus Neutralization Assay Pre-IND Meeting with U.S. FDA to be...
Kamada to Announce Second Quarter Ended June 30, 2020 Financial Results and Host Conference Call on August 12, 2020
August 05, 2020 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Kamada Announces Availability of its Plasma-Derived Hyperimmune IgG Therapy for Coronavirus Disease (COVID-19) for Compassionate Use Treatment in Israel
June 17, 2020 07:00 ET
|
Kamada Ltd.
Kamada Completed Manufacturing and Released the First Batch of its Plasma-Derived Immunoglobulin Product for Coronavirus Disease (COVID-19) and it is Available for Compassionate Use Treatment in...
Kamada Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Progress
May 18, 2020 07:00 ET
|
Kamada Ltd.
Total Revenues were $33.3 Million, an Increase of 24% Year-over-YearNet Income was $5.2 Million, an Increase of 6% Year-over-YearCompany Reports Continued Progress of its Development Program of a...
Kamada to Announce First Quarter Ended March 31, 2020 Financial Results and Host Conference Call on May 18, 2020
May 11, 2020 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, May 11, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Kamada and Kedrion Biopharma Announce Global Collaboration for the Development, Manufacturing and Distribution of a Plasma-Derived Anti-SARS-CoV-2 (COVID-19) Polyclonal Immunoglobulin Product
April 27, 2020 07:00 ET
|
Kamada Ltd.
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s ResponsibilityKedrion is...
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobulin (IgGs) Platform Technology including its Commercial Anti-Rabies IgG and its Pipeline Products Anti-Corona (COVID-19) and Anti-Zika IgGs
March 11, 2020 07:00 ET
|
Kamada Ltd.
Kamada Plans to Utilize its Hyper-Immunoglobulin (IgG) Platform Technology to Develop an Anti-Corona (COVID-19) Immunoglobulin as a Potential Therapy for Severely Ill Coronavirus Patients Kamada is...
Kamada Files Annual Report for the Year Ended December 31, 2019
February 26, 2020 09:30 ET
|
Kamada Ltd.
REHOVOT, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it has filed its annual report on Form 20-F...
Kamada Reports Financial Results for Fourth Quarter and Fiscal Year 2019
February 12, 2020 07:00 ET
|
Kamada Ltd.
Total Revenues for Fiscal 2019 were $127.2 million, up 11% as Compared to 2018Gross Profit for Fiscal 2019 was $49.7 Million, up 20% as Compared to 2018Adjusted EBITDA for Fiscal 2019 was $28.5...
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2019 Financial Results and Host Conference Call on February 12, 2020
February 05, 2020 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for...